US2012082677A1PendingUtilityA1

Compositions for the treatment of hcv and hbv

16
Assignee: ABDUL AZIZ SHERIF SALAHPriority: Oct 1, 2010Filed: Oct 1, 2010Published: Apr 5, 2012
Est. expiryOct 1, 2030(~4.2 yrs left)· nominal 20-yr term from priority
Inventors:Sherif Salah Abdul Aziz
A61K 31/195A61K 39/40A61P 31/14G01N 2333/9126G01N 2333/75G01N 2333/968A61P 31/04A61K 38/45G01N 33/5767
16
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Therapeutic compositions for the treatment of viral hepatitis B (HBV) and hepatitis C (HCV) comprise antistreptokinase and antistreptolysine antibodies and/or tranexamic acid. Three antibodies against: polymerase, plasmin activators and fibrin are found in the blood of hepatitis C infected patients.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition for the treatment of hepatitis B or hepatitis C comprising tranexamic acid. 
     
     
         2 . The pharmaceutical composition according to  claim 1  further comprising an antistreptolysin antibody. 
     
     
         3 . The pharmaceutical composition according to  claim 1  further comprising an antistreptokinase antibody. 
     
     
         4 . The pharmaceutical composition according to  claim 3  further comprising an antistreptolysin antibody. 
     
     
         5 . The pharmaceutical composition according to  claim 4  further comprising a DNA pfu polymerase enzyme of bacterial origin. 
     
     
         6 . A pharmaceutical composition for the treatment of hepatitis B or hepatitis C comprising an antistreptolysine antibody and an antistreptokinase antibody. 
     
     
         7 . A pharmaceutical composition for the treatment of hepatitis B or hepatitis C comprising DNA pfu polymerase enzyme of bacterial origin. 
     
     
         8 . The pharmaceutical composition according to  claim 7  further comprising an antistreptolysine antibody. 
     
     
         9 . The pharmaceutical composition according to  claim 6  wherein the antibodies are human antibodies. 
     
     
         10 . The pharmaceutical composition as claimed in  claim 6  wherein the antibodies are monoclonal antibodies. 
     
     
         11 . The pharmaceutical composition as claimed in  claim 6  wherein the antibodies are polyclonal antibodies. 
     
     
         12 . A method for detecting hepatitis C in a patient comprising detecting the presence of an antiplasmin antibody, an antifibrin antibody and an antipolymerase antibody in a serum sample of the patient. 
     
     
         13 . The method according to  claim 12  further comprising detecting the presence of tissue plasminogen activator inhibitors TPI or TPII in the blood of the patient.

Join the waitlist — get patent alerts

Track US2012082677A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.